We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Definiens to Present Image Analysis Software for Clinical Trials and Translational Research at ASCO Meeting 2010

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Definiens to Present Image Analysis Software for Clinical Trials and Translational Research at ASCO Meeting 2010"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Definiens, the number one Enterprise Image Intelligence® company, has presented its image analysis software for use in clinical trials and translational research at this year’s annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, from June 4th to 8th.

Definiens software enables personalized medicine by providing oncology researchers and drug developers with deeper insights into the underlying biology of cancer from the analysis of digital pathology and non-invasive medical images.

Definiens digital pathology image analysis software allows pathologists to accurately identify, quantify and interpret biomarkers and cellular morphology in tissue samples on a cell-by-cell basis. With Definiens Tissue Studio™ researchers have the ability to make earlier, more informed drug prioritization decisions by validating drug-target interaction as well as the measurement of surrogate biomarkers for toxicity.

Additionally, Definiens Tissue Studio™ provides automated biomarker and morphological analysis for translational research in retrospective or prospective settings.

Definiens radiology software supports the volumetric analysis of lesions and organs over time. A recent study conducted with Merck & Co. demonstrated that volumetric insight, gained with Definiens software, can provide earlier indications of a candidate compound’s efficacy, potentially shortening clinical trials and providing substantial cost savings, according to the company.